Mycophenolate mofetil, azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac transplantation

Scandinavian Journal of Immunology

Volumn 45, Issue 4, 1997, Pages 343-348

  Ostraat O ^a   Qi, Z ^b   Olausson, M ^a   Tufveson, G ^c   Ekberg, H ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ROQUINIMEX;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOMODULATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030966725     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-407.x     Document Type: Article

References (42)

1. Freis D, Kechrid C, Charpentier B, Hammouche M, Moulin B. A prospective study of a triple association: cyclosporine, corticosteroids and azathioprine in immunologically high risk renal transplantation. Transplant Proc 1985;18:1231-3.
2. Squifflet J-P, Sutherland DER, Rynasiewicz JJ, Field J, Heil J, Najarian JS. Combined immunosuppressive therapy with cyclosporin A and azathioprine. Transplantation 1982;6:315-18.
3. Illner WD, Land W, Haberstetzer R et al. Cyclosporine in combination with azathioprine and steroids in cadaveric renal transplantation. Transplant Proc 1985;17:1181-2.
4. Simmonds RL, Canafax DM, Strand M et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prenisolone. Transplant Proc 1985;17:266-9.
5. Slapak M, Geoghegan T, Digard N, Ahmed K, Sharman VL, Crockett R. The use of low dose cyclosporine in combination with azathioprine and steroids in renal transplantation. Transplant Proc 1985;17:1222-7.
6. Elion GP. Biochemistry and pharmacology of purin analogues. Fed Proc 1967;26:898-904.
7. Brinker KR, Dickerman RM, Gonwa TA et al. A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 1990;50:43-9.
8. Lindholm A, Albrechtsen D, Tufvesson G, Karlberg I, Persson NH, Groth CG. A Randomized trial of cyclosporine and prednisolone versus cyclosporine, azathioprine, and prednisolone in primary cadaveric renal transplantation. Transplantation 1992;54:624-31.
9. Ponticelli C, Tarantino A, Montagnino G et al. A randomized trial comparing trippel-drug and double-drug therapy in renal transplantation. Transplantation 1988;45:913-18.
10. Wheeler GP. Some biochemical effects of alkylating agents. Fed Proc 1967;26:885-9.
11. Starzl TE, Putnam CW, Halgrimson CG et al. Cyclophosphamide and hole organ transplantation in human beings. Surg Gyn Obst 1971;133:981-91.
12. Starzl TE, Penn I. Schroter G et al. Cyclophosphamide and human organ transplantation. Lancet 1971;2:70-4.
13. Starzl TE, Groth CG, Putnam W et al. Cyclophosphamide for clinical renal and hepatic transplantation. Transplant Proc 1973;1:511-16.
14. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991;1:27-31.
15. Sweeney MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Research 1972;32:1803-9.
16. Figueroa J, Fuad S, Kunjummen D, Platt JL, Bach FH. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443). Transplantation 1993;6:371-4.
17. Morris RE, Hoyt EG, Murphy MP, Eugui EM. Allison AC. Mycophenolic acid morpho-linoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejecton by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990;4:1659-62.
18. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995;59:460-6.
19. Fujino Y, Kawamura T, Hullett DA, Sollinger HW. Evaluation of cyclosporine, mycophenolate mofetil, and brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation. Transplantation 1994;1:41-6.
20. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
21. Sollinger HW. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-32.
22. Tufvesson G, Gannedahl G, Johnsson C, Olausson M, Wanders A, Ekberg H. New immunosuppressants: Testing and development in animal models and the clinic: With special reference to DSG. Immunol Rev 1993;36:99-109.
23. Wanders A, Gerdin B, Tufvesson G. Abolition of the effect of cyclosporin on rat cardiac allograft rejection by the new immunomodulator LS-2616 (linomide). Transplantation 1989;47:216-17.
24. Wanders A, Vogt P, Karlsson-Parra A, Wonigkeit K, Gerdin B, Tufvesson G. Evidence that LS-2616 (linomide) causes acute rejection of rat allografts protected by cyclosporin but not of long-term surviving allografts. Transplantation 1991;52:234-8.
25. Gannedahl G, Wanders A, Carlsson M, Tufvesson G. 15-deoxyspergualin, effects in rat heart allograft transplantation - relation to dose, timing and cyclosporine. Transplantation 1993;55:455-6.
26. Bersztel A, Wanders A, Wadström J et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK 506 in a rat heart allograft transplantation model. Transplant Proc 1995;27:3547-8.
27. Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990;144:4472-6.
28. Spetz-Hagberg AL, Larsson-Sciard EL. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after linomide treatment. Res Immunol 1989;140:517-25.
29. Larsson E-L, Joki A, Stålhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharm 1987;9:425-31.
30. Johnsson C, Tufveson G. The immunomodulator LS-2616 (Linomide) more effectively than sensitization of the donor enhances graft-versus-host reaction after small bowel transplantation. Transplant Immunol 1994;2:56-60.
31. Karussis DM, Lehmann D, Slavin S et al. Treatment of chronicrelapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993;90:6400-4.
32. Karussis DM, Lehmann D, Brenner T et al. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 1994;55:187-93.
33. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 1994;37:1195-201.
34. Spetz-Hagberg AL, Goldschmidt TJ, Stålhandske T, Larsson-Sciard EL. Amelioration of intrathymic T cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. Int Immunol 1990;2:645-50.
35. Olausson M, Mjörnstedt L, Lindholm L, Brynger H. Non suture organ grafting to neck vessels in rat. Acta Chir Scand 1984;15:463-7.
36. Turk JL, Parker D, Poulter LV. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 1972;23:493-501.
37. Winearls CG, Millard PR, Morris PJ. Effect of azathioprine and prednisolone on passive enhancement of rat renal allografts. Transplantation 1978;25:229-34.
38. Östraat Ö, Qi Z, Gannedahl G, Tufvesson G, Ekberg H. Moderat additiv immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation. Transplant Immunol 1996;4:241-6.
39. Olausson M, Arvidsson N, Lukes D et al. Inhibition of ATG-induced experimental transplantation tolerance with LS 2616. Transplant Proc 1995;27:3541-2.
40. Starzl TE, Demetris AJ, Murase N, Thomson AW, Trucco M, Ricordi C. Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today 1993;6:326-32.
41. Thomson AW, Starzl TE. New immunosuppressive drugs: Mechanistic insights and potential therapeutic advances, Immunol Rev 1993;136:71-98.
42. Murase N, Starzl TE, Demetris AJ et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 1993;4:701-8.